3-(1',1'-dimethylpentyl)-Δ⁸-tetrahydrocannabinol | 22663-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-(1',1'-dimethylpentyl)-Δ⁸-tetrahydrocannabinol
• 英文别名: (6aR,10aR)-6,6,9-trimethyl-3-(2-methylhexan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol；(6aR,10aR)-6,6,9-trimethyl-3-(2-methylhexan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
• CAS: 22663-41-8
• 化学式: C₂₃H₃₄O₂
• 分子量: 342.522
• InChiKey: ADXMNDLGCLUVBL-QZTJIDSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(1',1'-dimethylpentyl)-Δ⁸-tetrahydrocannabinol 在 氢氧化钾 、 selenium(IV) oxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-methoxy-3-(1',1'-dimethylpentyl)-11-oxo-Δ8-THC
  参考文献：
  名称：

  1-甲氧基，1-脱氧-11-羟基和11-羟基-1-甲氧基-Delta（8）-四氢大麻酚：CB2受体的新选择性配体。

  摘要：

  准备了三个系列的新大麻素，并确定了它们与CB（1）和CB（2）大麻素亲和力的亲和力。这些是1-甲氧基-3-（1'，1'-二甲基烷基）-，1-脱氧-11-羟基-3-（1'，1'-二甲基烷基）-和11-羟基-1-甲氧基-3 -（1'，1'-二甲基烷基）-Delta（8）-四氢大麻酚，其中含有从二甲基乙基到二甲基庚基的烷基链，该烷基链附加在大麻素的C-3上。所有这些化合物对CB（2）受体的亲和力均大于对CB（1）受体的亲和力，但是只有1-甲氧基-3-（1'，1'-二甲基己基）-Delta（8）-THC（JWH- 229，6e）实际上对CB（1）受体没有亲和力（K（i）= 3134 +/- 110nM），对CB（2）的亲和力很高（​​K（i）= 18 +/- 2nM）。

  DOI：

  10.1016/s0968-0896(02)00331-0
• 作为产物：
  描述：

  2-(3,5-dimethoxyphenyl)-2-methylpropanal 在 palladium 10% on activated carbon 、 氢气 、 三溴化硼 、 对甲苯磺酸 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 、 甲苯 为溶剂， -78.0~80.0 ℃ 、101.33 kPa 条件下， 反应 75.0h， 生成 3-(1',1'-dimethylpentyl)-Δ⁸-tetrahydrocannabinol
  参考文献：
  名称：

  [EN] CANNABINOIDS AND USES THEREOF
  [FR] CANNABINOÏDES ET LEURS UTILISATIONS

  摘要：

  该发明涉及大麻素化合物、包括一个或多个大麻素化合物的药物组合物，以及利用包括一个或多个大麻素化合物的药物组合物治疗患有疾病或症状（例如，纤维化疾病或炎症性疾病）的患者的用途。

  公开号：

  WO2019232413A1

文献信息

• 3-(1′,1′-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor
  作者：John W. Huffman、John Liddle、Shu Yu、Mie Mie Aung、Mary E. Abood、Jenny L. Wiley、Billy R. Martin

  DOI：10.1016/s0968-0896(99)00219-9

  日期：1999.12

  and CB2 receptors were determined employing previously described procedures. Five of the 3-(1',1'-dimethylalkyl)-1-deoxy-delta8-THC analogues (2, n = 1-5) have high affinity (Ki = < 20 nM) for the CB2 receptor. Four of them (2, n = 1-4) also have little affinity for the CB1 receptor (Ki = > 295 nM). 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC (2, n = 2) has very high affinity for the CB2 receptor (Ki

  描述了15个1-deoxy-delta8-THC类似物的合成和药理作用，其中一些对CB2受体具有高亲和力。所述脱氧大麻素包括1-脱氧-11-羟基-δ8-THC（5），1-脱氧δ8-THC（6），1-脱氧-3-丁基-δ8-THC（7），1-脱氧-3 -hexyl-delta8-THC（8）和一系列3-（1'，1'-二甲基烷基）-1-deoxy-delta8-THC类似物（2，n = 0-4，6，7，其中n =侧链中的碳原子数-2）。还制备了脱氧萘丁酮（16）的三种衍生物（17-19）。使用前述方法确定每种化合物对CB1和CB2受体的亲和力。3-（1'，1'-二甲基烷基）-1-脱氧-delta8-THC类似物中的五个（2，n = 1-5）对CB2受体具有高亲和力（Ki = <20 nM）。其中四个（2，n = 1-4）对CB1受体的亲和力也很小（Ki => 295 nM）。3-（1'，1'-二
• Structure–activity relationships for 1′,1′-dimethylalkyl-Δ 8 -tetrahydrocannabinols
  作者：John W Huffman、John R.A Miller、John Liddle、Shu Yu、Brian F Thomas、Jenny L Wiley、Billy R Martin

  DOI：10.1016/s0968-0896(02)00649-1

  日期：2003.4

  A series of 1',1'-dimethylalkyl-Delta(8)-tetrahydrocannabinol analogues with C-3 side chains of 2-12 carbon atoms has been synthesized and their in vitro and in vivo pharmacology has been evaluated. The lowest member of the series, 1',1'-dimethylethyl-Delta(8)-THC (8, n = 0) has good affinity for the CB1 receptor, but is inactive in vivo. The dimethylpropyl (8, n = 1) through dimethyldecyl (8, n = 8) all have high affinity for the CB1 receptor and are full agonists in vivo. 1',1'-Dimethylundecyl-Delta(8)-THC (8, n = 9) has significant affinity for the receptor (K-i = 25.8 +/- 5.8 nM), but has reduced potency in vivo. The dodecyl analogue (8, n = 10) has little affinity for the CB1 receptor and is inactive in vivo. A quantitative structure-activity relationship study of the side chain region of these compounds is consistent with the concept that for optimum affinity and potency the side chain must be of a length which will permit its terminus to loop back in proximity to the phenolic ring of the cannabinoid. (C) 2003 Elsevier Science Ltd. All rights reserved.
• 1-Bromo-3-(1′,1′-dimethylalkyl)-1-deoxy-Δ8-tetrahydrocannabinols: New selective ligands for the cannabinoid CB2 receptor
  作者：John W. Huffman、Seon A. Hepburn、Nataliya Lyutenko、Alicia L.S. Thompson、Jenny L. Wiley、Dana E. Selley、Billy R. Martin

  DOI：10.1016/j.bmc.2010.09.061

  日期：2010.11.15

  Delta(8)-Tetrahydrocannabinol (26), 3-(1',1'-dimethylbutyl)- (12), 3-(1',1'-dimethylpentyl)- (13), 3-(1',1'-dimethylhexyl)- (14) and 3-(1',1'-dimethylheptyl)-Delta(8)-tetrahydrocannabinol (15) have been converted into the corresponding 1-bromo-1-deoxy-Delta(8)-tetrahydrocannabinols (25, 8-11). This was accomplished using a protocol developed in our laboratory in which the trifluoromethanesulfonate of a phenol undergoes palladium mediated coupling with pinacolborane. Reaction of this dioxaborolane with aqueous-methanolic copper(II) bromide provides the aryl bromide. The affinities of these bromo cannabinoids for the cannabinoid CB1 and CB2 receptors were determined. All of these compounds showed selectivity for the CB2 receptor and one of them, 1-bromo-1-deoxy-3-(1',1'-dimethylhexyl)-Delta(8)-tetrahydrocannabinol (10), exhibits 52-fold selectivity for this receptor with good (28 nM) affinity. (C) 2010 Elsevier Ltd. All rights reserved.
• CANNABINOIDS AND USES THEREOF
  申请人：Corbus Pharmaceuticals, Inc.

  公开号：US20210284621A1

  公开（公告）日：2021-09-16

  The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a disease or condition (e.g., a fibrotic disease or an inflammatory disease) in a subject in need thereof.
• [EN] CANNABINOIDS AND USES THEREOF<br/>[FR] CANNABINOÏDES ET LEURS UTILISATIONS
  申请人：CORBUS PHARMACEUTICALS INC

  公开号：WO2019232413A1

  公开（公告）日：2019-12-05

  The invention relates to cannabinoid compounds, pharmaceutical compositions including one or more cannabinoid compounds, and the use of pharmaceutical compositions including one or more cannabinoid compounds for the treatment of a disease or condition (e.g., a fibrotic disease or an inflammatory disease) in a subject in need thereof.

  该发明涉及大麻素化合物、包括一个或多个大麻素化合物的药物组合物，以及利用包括一个或多个大麻素化合物的药物组合物治疗患有疾病或症状（例如，纤维化疾病或炎症性疾病）的患者的用途。